Vitamin D and HIV-Cardiovascular Disease in Children and Young Adults
Vitamin D Metabolism Inflammation, and Cardiovascular Risk in HIV-infected Children and Young Adults
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Emory Chldren's Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals Case Medical Center, Case Western Reserve University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria - Documentation of HIV Infection Between ages of 8 and 25
- On stable ART for at least 12 weeks for the HIV+ patients
- Cumulative duration of ART for at least 48 weeks for HIV + patients
- Healthy child/young adult with age and race matched to HIV+ patient for the HIV- controls
- Absence of HIV based on medical and medication history
Exclusion Criteria:
- Taking > 800 IU of Vitamin D per day
- Parathyroid or Calcium disorders
- Acute illness and active inflammatory condition
- Chronic illnesses that include malignancy, diabetes, CAD
- Pregnancy and lactation
- Creatinine Clearance <50 ml/min
- Hgb < 9.0 g/dL
- AST and ALT > 2.5 upper limits of normal
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
HIV+
HIV Positive children or young people between the ages of 8 and 25
|
|
HIV Negative
HIV Negative matched controls by age and race
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Vitamin D levels
Time Frame: One time point at entry
|
To perform a cross-sectional analysis of blood vitamin D status among the HIV-infected children and young adults to evaluated the point prevalence fo plasma 25(OH)D levels indicating vitamin D insufficiency, deficiency and severe deficiency, and to compare the prevalence to a matched uninfected healthy control group.
|
One time point at entry
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Allison Ross Eckard, MD, Emory-Children's Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1R01HD070490-01 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.